^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    decitabine/ tetrahydrouridine (EPI01)

    i
    Other names: EPI01, EPI 01, NN7533, NN 7533, Eclipse, NDec
    Company:
    EpiDestiny, Novo Nordisk
    Drug class:
    Cytidine deaminase inhibitor, DNA methylation inhibitor
    Related drugs:
    2ms
    ASCENT1: Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (clinicaltrials.gov)
    P2, N=96, Completed, Novo Nordisk A/S | Active, not recruiting --> Completed | Trial primary completion date: Aug 2025 --> Dec 2024
    Trial completion • Trial primary completion date
    |
    hydroxyurea • decitabine/ tetrahydrouridine (EPI01)
    6ms
    A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P1, N=20, Recruiting, EpiDestiny, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    decitabine/ tetrahydrouridine (EPI01)
    6ms
    A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS) (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, EpiDestiny, Inc.
    New P1 trial
    |
    decitabine/ tetrahydrouridine (EPI01)
    6ms
    A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease (clinicaltrials.gov)
    P1, N=20, Recruiting, EpiDestiny, Inc. | Trial completion date: Apr 2024 --> Apr 2027 | Trial primary completion date: Mar 2024 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    decitabine/ tetrahydrouridine (EPI01)
    7ms
    To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males (clinicaltrials.gov)
    P1, N=10, Completed, EpiDestiny, Inc. | Recruiting --> Completed
    Trial completion
    |
    decitabine/ tetrahydrouridine (EPI01)
    7ms
    ASCENT1: Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (clinicaltrials.gov)
    P2, N=84, Active, not recruiting, Novo Nordisk A/S | Trial primary completion date: Dec 2024 --> Aug 2025 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date
    |
    hydroxyurea • decitabine/ tetrahydrouridine (EPI01)
    12ms
    A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People (clinicaltrials.gov)
    P1, N=44, Completed, Novo Nordisk A/S | Recruiting --> Completed
    Trial completion
    |
    decitabine/ tetrahydrouridine (EPI01)
    over1year
    A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People (clinicaltrials.gov)
    P1, N=48, Recruiting, Novo Nordisk A/S | Not yet recruiting --> Recruiting
    Enrollment open
    |
    decitabine/ tetrahydrouridine (EPI01)
    almost2years
    A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, Novo Nordisk A/S
    New P1 trial
    |
    decitabine/ tetrahydrouridine (EPI01)
    2years
    ASCENT1: Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (clinicaltrials.gov)
    P2, N=84, Recruiting, Novo Nordisk A/S | Trial primary completion date: Nov 2023 --> Oct 2024
    Trial primary completion date
    |
    hydroxyurea • decitabine/ tetrahydrouridine (EPI01)